IDEAYA Biosciences shares are trading higher after the company announced interim Phase 2 monotherapy expansion data for IDE397 in MTAP-deletion urothelial and lung cancer. Additionally, Mizuho initiated coverage on the stock with an Outperform rating.
Portfolio Pulse from Benzinga Newsdesk
IDEAYA Biosciences shares are trading higher following the announcement of positive interim Phase 2 data for IDE397 in MTAP-deletion urothelial and lung cancer. Mizuho also initiated coverage on the stock with an Outperform rating.
July 08, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IDEAYA Biosciences shares are trading higher due to positive interim Phase 2 data for IDE397 in MTAP-deletion cancers and an Outperform rating from Mizuho.
The positive interim Phase 2 data for IDE397 in MTAP-deletion cancers is a significant milestone for IDEAYA Biosciences, likely boosting investor confidence. Additionally, Mizuho's Outperform rating further supports a positive outlook for the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100